This is the first trial combining Allarity’s stenoparib with another anti-cancer agentStenoparib’s favorable safety profile supports ...

Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a common complication of small cell lung cancer (SCLC). It can cause many symptoms related to low sodium or other electrolyte ...

Frontline: Surgery to remove the tumor is often considered, sometimes followed by chemotherapy or radiation to reduce ...

Tarlatamab (Imdelltra) is a new type of immunotherapy approved for people with small-cell lung cancer whose disease has progressed after chemotherapy and immunotherapy.

Is Zepzelca Right for Me? To help choose the right treatment for you, your health care provider will consider what type of lung cancer you have, the treatments you have received, and whether the ...

The therapeutic landscape of small cell lung cancer (SCLC) is undergoing a paradigm shift with the emergence of delta-like ligand-3 (DLL3)–directed therapies, particularly tarlatamab, a first-in-class ...

A new randomized clinical trial showed that receiving immunochemotherapy infusions earlier in the day may help patients with ...

Small cell lung cancer (SCLC) is one of the most aggressive forms of lung cancer, with a five-year survival rate of only 5%. Despite this poor prognosis, SCLC is initially highly responsive to ...

Filippo Beleggia, MD, PhD, didn’t believe his own data. As a postdoctoral researcher, he spent years in the laboratory of Christian Reinhardt, MD, PhD, at the University Hospital Cologne, Cologne, ...

Novartis has nixed six early-stage pipeline programs, swapping in two new phase 1 cancer candidates as replacements. | ...